Skip to content
Trial Eligibility
Menu

Natural History Study of CADASIL

NCT05072483

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

Background: CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy) is a genetic disorder. It causes narrowing of the small blood vessels and can lead to strokes and dementia. Researchers want to monitor people with CADASIL over time. Objective: To learn more about how CADASIL affects a person s blood vessels over time. Eligibility: Adults ages 18 and older who have CADASIL, and healthy volunteers. Design: Participants will be screened with a medical record review. Participants will have 4 study visits over 9 years.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Cardiovascular Disease
  • Arterial Stiffness
  • Germline Mutation in the NOTCH 3 Gene
  • Pathogenesis of CADASIL
  • Clinical Phenotype of CADASIL

Eligibility basics and study details

Study type
Observational
Phase
Not applicable
Ages
18 to 100 years
Sex
All
Healthy volunteers
Accepted
Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Last updated on ClinicalTrials.gov
October 8, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

Maryland · 1

  • National Institutes of Health Clinical Center · Bethesda, MD

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.